ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 145 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2021. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $8,335,017 | +464.2% | 3,754,512 | +581.1% | 0.00% | – |
| Q1 2024 | $1,477,347 | +28.8% | 551,249 | +43.6% | 0.00% | – |
| Q4 2023 | $1,147,410 | +287.1% | 383,749 | +26.9% | 0.00% | – |
| Q3 2023 | $296,400 | -29.5% | 302,449 | 0.0% | 0.00% | – |
| Q2 2023 | $420,404 | -86.1% | 302,449 | -84.1% | 0.00% | – |
| Q1 2023 | $3,026,428 | -86.2% | 1,903,414 | -45.8% | 0.00% | -100.0% |
| Q4 2022 | $21,858,690 | +112.8% | 3,508,618 | +128.9% | 0.00% | 0.0% |
| Q3 2022 | $10,272,000 | +29.8% | 1,533,148 | +23.2% | 0.00% | – |
| Q2 2022 | $7,915,000 | +86.1% | 1,244,539 | +35.8% | 0.00% | – |
| Q1 2022 | $4,252,000 | -18.7% | 916,438 | -12.4% | 0.00% | – |
| Q4 2021 | $5,232,000 | -24.8% | 1,046,377 | +81.3% | 0.00% | – |
| Q3 2021 | $6,956,000 | -85.4% | 577,281 | -74.4% | 0.00% | -100.0% |
| Q2 2021 | $47,634,000 | -19.8% | 2,252,194 | +6.3% | 0.00% | 0.0% |
| Q1 2021 | $59,422,000 | -9.4% | 2,118,446 | -16.0% | 0.00% | -25.0% |
| Q4 2020 | $65,586,000 | -2.1% | 2,522,544 | +39.9% | 0.00% | -20.0% |
| Q3 2020 | $67,008,000 | -25.3% | 1,802,750 | +3.2% | 0.01% | -28.6% |
| Q2 2020 | $89,674,000 | +157.0% | 1,747,696 | +57.9% | 0.01% | +133.3% |
| Q1 2020 | $34,892,000 | -46.9% | 1,106,617 | +0.5% | 0.00% | -25.0% |
| Q4 2019 | $65,683,000 | +24.2% | 1,101,509 | -23.6% | 0.00% | 0.0% |
| Q3 2019 | $52,877,000 | -28.6% | 1,442,360 | -9.5% | 0.00% | -33.3% |
| Q2 2019 | $74,105,000 | +33.0% | 1,592,981 | +14.8% | 0.01% | +50.0% |
| Q1 2019 | $55,732,000 | -19.6% | 1,388,090 | -7.9% | 0.00% | -33.3% |
| Q4 2018 | $69,333,000 | -15.3% | 1,507,249 | -18.3% | 0.01% | 0.0% |
| Q3 2018 | $81,899,000 | -3.9% | 1,845,808 | -15.1% | 0.01% | -14.3% |
| Q2 2018 | $85,191,000 | -10.4% | 2,173,737 | +65.3% | 0.01% | -12.5% |
| Q1 2018 | $95,091,000 | +23.6% | 1,314,713 | +12.5% | 0.01% | +33.3% |
| Q4 2017 | $76,961,000 | +21.8% | 1,168,832 | -7.3% | 0.01% | +20.0% |
| Q3 2017 | $63,166,000 | -9.4% | 1,260,414 | -16.3% | 0.01% | -16.7% |
| Q2 2017 | $69,721,000 | +377.8% | 1,506,514 | +264.6% | 0.01% | +500.0% |
| Q1 2017 | $14,592,000 | +388.2% | 413,222 | +73.3% | 0.00% | – |
| Q4 2016 | $2,989,000 | -11.5% | 238,482 | -2.2% | 0.00% | – |
| Q3 2016 | $3,377,000 | +38.5% | 243,746 | -1.0% | 0.00% | – |
| Q2 2016 | $2,438,000 | -42.0% | 246,271 | -1.0% | 0.00% | – |
| Q1 2016 | $4,207,000 | -82.5% | 248,828 | -76.9% | 0.00% | -100.0% |
| Q4 2015 | $23,983,000 | +39.6% | 1,077,466 | +48.0% | 0.00% | +50.0% |
| Q3 2015 | $17,174,000 | -59.8% | 727,877 | +39.3% | 0.00% | -60.0% |
| Q2 2015 | $42,712,000 | +17.4% | 522,420 | +33.0% | 0.01% | +25.0% |
| Q1 2015 | $36,379,000 | +1085.8% | 392,848 | +417.4% | 0.00% | – |
| Q4 2014 | $3,068,000 | +161.1% | 75,926 | +58.0% | 0.00% | – |
| Q3 2014 | $1,175,000 | +78.0% | 48,054 | +15.5% | 0.00% | – |
| Q2 2014 | $660,000 | +8.6% | 41,603 | +3.9% | 0.00% | – |
| Q1 2014 | $608,000 | +17.8% | 40,043 | +6.7% | 0.00% | – |
| Q4 2013 | $516,000 | -9.3% | 37,533 | +24.3% | 0.00% | – |
| Q3 2013 | $569,000 | – | 30,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $98,242,000 | 23.93% |
| Rhenman & Partners Asset Management AB | 655,854 | $24,044,000 | 3.01% |
| Bellevue Group AG | 4,241,461 | $155,492,000 | 2.89% |
| Boxer Capital, LLC | 975,000 | $35,744,000 | 2.59% |
| Pentwater Capital Management LP | 2,478,261 | $90,853,000 | 1.42% |
| HAMILTON LANE ADVISORS LLC | 52,826 | $1,937,000 | 0.81% |
| Tekla Capital Management LLC | 213,562 | $7,829,000 | 0.34% |
| Granahan Investment Management | 154,628 | $5,669,000 | 0.31% |
| Spark Investment Management LLC | 64,900 | $2,379,000 | 0.30% |
| WASATCH ADVISORS LP | 630,397 | $23,110,000 | 0.22% |